Хроническая почечная недостаточность, ч. 2
Dunea G., Swagel M., Bodiwala U., Arruda J. Intradialytic oral iron therapy//Int. J. Artif. Organs. — 1994. — Vol. 17. — P. 261-264.
Eidemark I., Friedberg M., Ladefoged S. et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD//Nephrol. Dial. Transplant. — 1991. — Vol. 7. — P. 526-529.
Erem C., Kulan K., Tuncer C. et al. Cardiac arrhythmias in patients on maintenance hemodialysis//Acta Cardiol. — 1997. — Vol. 52. — P. 25-36.
Fantuzzi S, Caico S., Amatruda O. et al. Hemodialysis-associated cardiac arrhythmias: a lower risk with bicarbonate?//Nephron. — 1991. — Vol. 58. — P. 196-200.
Farmer C, Goldsmith D., Sharpstone P., Kingsswood J. Maintenance of adequate dialysis in patient with peritoneal calcification using tidal peritoneal dialysis// Clin. Nephrol. — 1998. — Vol. 49. — P. 55-58.
Fenton S., Schaubel D., Desmeules M. et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates//Am. J. Kidney Dis. — 1997. — Vol. 30. — P. 334-342.
Fishbane S., Galgano C., Langley R. et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients//Kidney Int. — 1997. — Vol. 52. — P. 217-222.
Fudin R., Jaichenko J., Shostak A., Bennett M., Gotloib L. Correction of uremic iron deficiency anemia in Hemodialyzed Patients: a prospective study//Nephron. — 1998. — Vol. 79. — P. 299-305.
Gastaldello K., Vereestraeten A., Nzame-Nze T. et al. Resistence to erythropoietin in iron-overloaded hemodialysis patients can be overcome by ascorbic acid administration//Nephrol. Dial. Transplant. — 1995. — Vol. 10. — Suppl. 6. — P. 44-47.
Gejyo F., Odani S., Yamada T. et al. ß2-Microglobulin: a new form of amyloid protein associated with chronic hemodialysis II//Kidney Int. — 1986. — Vol.30. — P. 385 -390.
Giordano C. Prolongation of survival for decade or more by low protein diet//In: Giordano C., Friedman E. (eds) Uremia. Pathobiology of patients treated for ten years or more. — Milan, 1981. — P. 4-7.
Giovannetti S., Maggiore Q. A low nitrogen diet with proteins of high biological value for severe chronic uremia//Lancet. — 1964. — Vol. 1. — P. 1000-1003.
Golan E., Radnay J., Goldman J. et al. Relation between transferrin saturation index and red cell size and haemoglobin content in haemodialysis patients//Nephrol. Dial. Transplant. — 1994. — Vol. 9. — P. 1030-1031.
Granolleras C., Zein A., Oules R. et al. Continuous administration of intravenous iron during haemodialysis //Nephrol. Dial. Transplant. — 1997. — Vol. 12. — P. 1007-1008.
Hasselwander O., Master D., Fogarty D. et al. Serum paraoxonase and platelet-activating factor acethydrolase in chronic renal failure//Clin. Chem. — 1988. — Vol. 44. — P. 179-181.
Horl W., Cavill I., Macdougall I.C. et al. How to diagnose and correct iron deficiency during r-huEPO therapy — a consensus report//Nephrol. Dial. Transplant. — 1996. — Vol. 11.— P. 246-250.
Ixkes M., Koopman M., Asker B. et al. Cimetidine improves GFR-estimation by the Cockcroft an Gault formula//Clin. Nephrol. — 1997. — Vol. 4. — P. 229-236.
Jaar B., Denis A., Viron B. et al. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation//Am. J. Nephrol. — 1997. — Vol. 17. — P. 399-405.
Khan G., Lewis F., Dasgupta M. ß2-Microglobulin amyloidosis presenting as esophageal perforation in a hemodialysis patients//Am. J. Nephrol. — 1997. — Vol. 17. — P. 524-527.
Kimura K., Tabei K., Asano T., Hosoda S. Cardiac arrythmias in hemodialysis patients//Nephron. — 1989. — Vol. 53. — P. 201-207.
Klahr S., Levey A., Beck G. et al. The effects of dietary protein restriction and blood pressure control on progression of chronic renal disease//New Engl. J. Med. — 1994. — Vol. 330. — P. 877-884.
Klefter R., Nielsen B. A hundred billion dollars a year on dialysis. How to calculate and what to compare?//Int. J. Artif. Organs. — 1998. — Vol. 21. — P. 319-320.
Kostner K., Clodi M., Bodlaj G. et al. Decreased urinary apolipoprotein (a) excretion in patient with impaired renal function//Europ. J. Clin. Invest. — 1998. — Vol. 28. — p. 447-452.
Kotaki M., Uday K., Henriquez M. et al. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin//Clin. Nephrol. — 1997. — Vol. 48. — p. 63-64.
Labonia W. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin//Am. J. Kidney Dis. — 1995. — Vol. 26. — P. 757-764.
Lash J., Smith E. Is folate supplementation necessary in dialysis patients?//Int. J. Artif. Organs. — 1990. — Vol. 13. — P. 785-786.
Lima D., Fonseca J., Godoy D. Baseline variables associated with early death and extended survival on dialysis//Renal Failure. — 1998. — Vol. 20. — P. 581-587.
Locatelli F., Albert! D., Graziani G. et al. Prospective randomized multicentre trial of effect of protein restriction on progression of chronic renal failure// Lancet. — 1991. — Vol. 337. — P. 1299-1304.
Macdougall I., Hutton R.D., Cavill I. et al. Poor response to treatment of renal anemia with erythropoetin corrected by iron given intravenously//Brit. J. Med. — 1989. — Vol. 299. — P. 157-158.
Macdougall I. Poor response to erythropoetin: practical guideness on investigation and management//Nephrol. Dial. Transplant. — 1995. — Vol. 10. — P. 607-614.
Macdougall J. Merits of percentage hypochromic red cells as marker of functional iron deficiency//Nephrol. Dial. Transplant. — 1998. — Vol. 13. — P. 847-849.
Macdougall I. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin //Nephrol. Dial. Transplant. — 1998. — Vol. 13. — Suppl. 2. — P. 230-270.
Magocsi M., Takacz Sz., Arati A. et al. Calcitriol enhances the effect of Rh-Epo on erythroid differentation//Int. J. Artif. Organs. — 1997. — Vol. 20. — P. 502.
Markowitz G.S., Kahn G.A., Feingold R.E. et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin//CIin. Nephrol. — 1997. — Vol. 48. — P. 34- 40.
Minetti L. Erythropoietin treatment in renal anemia. How high should the target hematocrit be?//J. Nephrol. — 1997. — Vol. 10. — P. 117-119.
Mith W. The influence of the diet on progression of renal insufficiency//Ann. Rev. Med. — 1984. — Vol. 35. — P. 249-264.
Miyake T., Kung C.K.-H., Goldwasser E. Purification of human erythropoietin//J. Biol. Chem. — 1977. — Vol. 252. — P. 5558-5564.
Moore M., Eggers P. Minorities have the highest incidens of end stage kidhey disease in the U.S.//Hypertension. — 1993. — Vol. 21. — P. 591.
Moore M. End-stage renal disease: a southern epidemic //Southern Med. J. — 1994. — Vol. 87. — P. 1013-1017.
Morita T., Suzuki M., Kamimura A., Hirasawa Y. Amyloidosis of a possible new type in patients receiving long-term hemodialysis//Arch. Path. — 1985. — Vol. 109 — P. 1029-1032.
Muirhead N., Bagrman J., Burgess E. et al. Evidence-based recomendation for the clinical use of recombinant human erythropoietin//Am. J. Kidney Dis. — 1995. — Vol. 26. — Suppl. 1. — P. 1-24.
Musolino R., De Domenico P., Troilo G. et al. Cerebral atrophy and cognitive impairment in long-term hemodialyzed patients//New Trends Exp. and Clin. Psychiatry. — 1992. — Vol. 8. — P. 119-125.
Nahas A., Masters-Thomas A., Brady S. et al. Selective effects of low protein diets in chronic renal disease//Brit. Med. J. — 1984. — Vol. 289. — P. 1337-1341.
Nelson S., Hawkins P., Richardson S. et al. Imaging of hemodialysis-associated amyloidosis with ml-serum amyloid P component//Lancet. — 1991. — Vol. 338. — P. 3350-3390.
Omenn G., Beresford S., Motulsky A. Preventing coronary heart disease: B vitamins and homocysteine//Circulation. — 1998. — Vol. 97. — P. 421-424.
Oymak O., Akpolat T., Arik N. et al. Hyperammonemic encephalopathy due to vitamin D - induced hypercalcemia in a uremic patients//Nephron. — 1994. — Vol. 66. — P. 369.
Perry I., Refsum H., Morris H. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middleagea british men//Lancet. — 1995. — Vol. 346. — P. 1395-1398.
Pietzak I., Czarnecki R., Baczyk K., Antoniewicz K. Uremic polyneuropathy in conservatively treated (non-dialyzed) or in dialyzed patients//Przeg. Lek. — 1996. — Vol. 53. — P. 544-548.
Potter G., Johnson R., Fink G. Role of endothelin in hypertension of experimental chronic renal failure//J. Am. Heart Ass. — 1997. — Vol. 30. — P. 1578-1584.
Ramirez G., Bruegeemeyer C., Newton J. Cardiac arrhythmias on hemodialysis in chronic renal failure patients//Nephron. — 1984. — Vol. 36. — P. 212-218.
Riley S., Rutherford S., Rutherford P. Low carnitine levels in hemodialysis patients: relationship with functional activity status and intradialytic hypotension//Clin. Nephrol. — 1997. — Vol. 48. — P. 392-393.
Ritz E., Amman K. Optimal haemoglobin during treatment with recombinant human erythropoietin//Nephrol. Dial. Transplant. — 1998. — Vol. 3. — Suppl. 2. — P. 16-22.
Rumble J., Cooper M., Soulis T. et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation products//J. Clin. Invest. — 1997. — Vol. 99. — P. 1016-1027.
Savage T., Giles M., Tomson C. and A.E.Raine. Gender differences in mediators of left ventricular hypertrophy in dialysis patients//Clin. Nephrol. — 1998. — Vol. 49. — P. 107-112.
Shibagaki Y., Takaichi K. Significant reduction of the large-vessel blood volume by food intake during hemodialysis//Clin. Nephrol. — 1998. — Vol. 49. — P. 49-54.
Silver S. Cerebral edema after hemodialysis: the "reverse urea effect* lives//Int. J. Artif. Organs. — 1998. — Vol. 21. — P. 247-250.
Siniukhin K, Stetsyuk E. Furancarboxylic acid - factor of hemodialysys anemia?//Int. J. Artif. Organs. — 1992. — Vol. 15. — P. 541.
Smans K., Van Landeghem G., D'Hae P. et al. Is there a link between erythropoietin therapy and adynamic bone disease?//Nephrol. Dial. Transplant. — 1996. — Vol. 11. — P. 1248-1249.
Sobh N., Sheashaa H., Tantawy A., Ghonein M. Study of effects of optimization of dialysis and protein intake on neuromuscular function in patients under maintenance hemodialysis treatment//Am. J. Nephrol. — 1998. — Vol. 18. — P. 399-403.
Sombolos K., Tsitamidou Z., Kyriazis G. et al. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo//Am. J. Nephrol. — 1997. — Vol. 17. — P. 406-412.
Stein G., Funfstuck R., Klemm A., Maiwald J. Protein-restriktion bei chronischer Niereninsuffizienz//Nieren und Hochdruckkrank. — 1997. — Bd 26. — S. 272-276.
Sulzbacher L., Delling G. Dialyseassoziierte Amyloidose als Ursache fur Schenkelhalsfrakturen//Nieren und Hochdruckkrank. — 1998. — Vol. 27. — S. 262-269.
Sumamoto M., Kuze K., Iehara N. et al. Expression of heat shock protein 47 is increased in remnant kidney and correlates with disease progression//Int. J. Exp. Path. — 1998. —Vol. 79. — P. 133-140.
Suzuki R., Tsumura K., Inoue T. et al. QT Interval prolongation in patients receiving maintenance hemodialysis//Clin. Nephrol. — 1998. — Vol. 49. — P. 240-244.
Tarng D., Huang T. Uraemic pericarditis: a reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients//Nephrol. Dial. Transpl. — 1997. — Vol. 12. — P. 1051-1054.
Toto R., Shuits L. et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment// Hypertension. — 1998. — Vol. 31. — P. 684-691.
Vita G,, Savica V., Milone S. et al. Uremic autonomic neuropathy: recovery following bicarbonate hemodialysis/ /Clin. Nephrol. — 1996. — Vol. 45. — P. 56-60.
Wcishio M., Okida S., Mizoue T. et al. Risk factors for left ventricular hypertrophy in chronic hemodialysis patients//Clin. Nephrol. — 1997. — Vol. 47. — P. 362-366.
Welter J., Wu S., Ferguson C., Hawthorne V. End-stage renal disease in Michigan//Arn. J. Nephrol. — 1995. — Vol. 5. — P. 84-95.
Woittiez A., Huysmans F., Bailey R. et al. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension//Clin. Nephrol. — 1998. — Vol. 49. — P. 160-166.
Wu Z., Bao X. Effects of benazepril on insulin resistance and glucose tolerance in uremia//Clin. Nephrol. — 1998. —Vol. 50. — P. 108-112.
Zazgornic J., Biesenbach G., Forsteinlehner M., Stum-mvoll K. Profile of antihypertensive drugs in hypertensive patients on renal - replacement therapy (RRT)//Clin. Nephrol. — 1997. — Vol. 48. — P. 337-340.
Игнатова M.C., Beльтищев Ю.E. Детская нефрология. — Л.: Meдицина, 1989. — 456 c.
Папаян А.B., Caвeнкова H.Д. Kлиническая нефрология детского возраста. — CПб., 1997. — 637 c.
Цыбышева А.К. Нарушения фосфорно-кальциевого обмена у детей с хронической почечной недостаточностью//Coвременные методы диагностики и лечения нефро-урологических заболеваний у детей. — 1998. — C. 103-107.
Комментарии
валентина 2010.09.17 18:17
Смотреть все комментарии - 1
Ваш комментарий